D-0038-2024 Class II Terminated
FDA drug recall D-0038-2024 was initiated by Zydus Pharmaceuticals (USA) Inc on Sep 21, 2023 and is designated Class II. Reason for recall: Failed Dissolution Specifications The recall status is terminated (terminated Aug 6, 2025). Affected quantity: 7,248 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 11, 2023
- Initiation Date
- Sep 21, 2023
- Termination Date
- Aug 6, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 7,248 bottles
Product description
Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 68382-256-01) and b) 500 tablets (NDC 68382-256-05) bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534
Reason for recall
Failed Dissolution Specifications
Distribution pattern
Nationwide in the USA.
Code information
Lot#: M300652 and M300651, exp. Dec 2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0038-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026